It has been found that 36% to 100% of patients with PDL1-positive tumor cells, detected via IHC, respond to PD1/PDL1 therapy; however, 0% to 17% of PDL1-negative patients also respond 15, suggesting that additional factors may be involved in predicting the response. The gene discussed is PDCD1; the disease is neoplasm.